Photo of Li Jia,  Ph.D.

Li Jia, Ph.D.

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 525-7397


ljia3@partners.org

Li Jia, Ph.D.

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Surgery, Harvard Medical School
  • Director of Urology Research, Surgery, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Prostate cancer is the most common non-skin cancer in America, affecting 1 in 7 men. While better screening and treatment have resulted in improved outcomes, a subset of patients eventually develops metastatic disease. Androgen deprivation therapy is initially effective, but incurable castration-resistant prostate cancer inevitably develops. While the new generation of anti-androgen therapies has shown promise, survival improvements have been measured in months. How prostate cancer cells acquire the ability to survive and proliferate after androgen deprivation therapy remains to be determined. Importantly, the failure of androgen deprivation therapy is not accompanied by the loss of androgen receptor (AR) or AR activity, but rather with restored AR activation through a variety of mechanisms. The focus of our research has been on elucidating AR-mediated gene expression and functions in androgen-dependent and castration-resistant prostate cancer. The goal of our research is to understand the mechanisms that lead to prostate cancer development and progression and translate that mechanistic understanding into therapeutics to prevent, delay and treat the disease.

Publications

Powered by Harvard Catalyst
  • Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, Schrag D, Kibel AS, Freedman ML. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer 2017. PubMed
  • Jia L, Gui B, Zheng D, Decker KF, Tinay I, Tan M, Wang X, Kibel AS. Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration. Prostate 2017; 77:1000-1011. PubMed
  • Koboldt DC, Kanchi KL, Gui B, Larson DE, Fulton R, Isaacs WB, Kraja A, Borecki IB, Jia L, Wilson RK, Mardis ER, Kibel AS. Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African-Americans. Cancer Epidemiol Biomarkers Prev 2016. PubMed
  • Zheng D, Gui B, Gray KP, Tinay I, Rafiei S, Huang Q, Sweeney CJ, Kibel AS, Jia L. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene 2016. PubMed
  • Zheng D, Decker KF, Zhou T, Chen J, Qi Z, Jacobs K, Weilbaecher KN, Corey E, Long F, Jia L. Role of WNT7B-induced noncanonical pathway in advanced prostate cancer. Mol Cancer Res 2013; 11:482-93. PubMed
  • Decker KF, Zheng D, He Y, Bowman T, Edwards JR, Jia L. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res 2012; 40:10765-79. PubMed
  • Ahmadiyeh N, Pomerantz MM, Grisanzio C, Herman P, Jia L, Almendro V, He HH, Brown M, Liu XS, Davis M, Caswell JL, Beckwith CA, Hills A, Macconaill L, Coetzee GA, Regan MM, Freedman ML. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A 2010; 107:9742-6. PubMed
  • Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 2009; 5:e1000597. PubMed